

# PARI REUSABLE NEBULIZERS



*LC® Sprint*

*LC® Plus*

## PARI REUSABLE NEBULIZERS

- ✓ Clinically proven reusable nebulizers
- ✓ FAST treatments – 5-6 minutes<sup>1</sup>
- ✓ Saves money by wasting less medication
- ✓ Breath-Enhanced design delivers consistent particle size & targeted delivery to the lungs
- ✓ Easy to clean – hand wash, boilable and dishwasher safe
- ✓ Easy to use for all ages
- ✓ Covered by insurance every 6 months<sup>2</sup>

**PARI.** The Clinical Choice.

# PARI REUSABLE NEBULIZERS

## INCLUDING PARI TIMESTRIP®




- ✓ Easy to use visual indicator
- ✓ Reminds patients to replace their PARI nebulizer every 6 months
- ✓ Helps maintain FAST treatments & reduce bacterial contamination<sup>3</sup>


## THE DIFFERENCE IS IN THE DELIVERY<sup>4</sup>

■ PARI LC® Sprint
 ■ PARI LC® Plus
 ■ Sidestream® Plus

### Drug Delivered to the Lungs



### Drug Delivered to the Lungs Per Minute



## CONFIGURATIONS

	Part No.	NDC No.	HCPs No.
PARI LC® Sprint	023F35	83490-0230-01	A7005
PARI LC® Plus	022F81	83490-0220-28	A7005
PARI LC® Sprint Retail	023F35-R	83490-0230-11	A7005
PARI LC® Plus Retail	022F81-R	83490-0221-36	A7005

## SPECIFICATIONS

### PARI LC® Sprint Performance<sup>1</sup>:

Total Output Rate	500 mg/min
MMD	3.5 µm
% RF	68%
Average Treatment Time	~5 min

### PARI LC® Plus Performance<sup>1</sup>:

Total Output Rate	440 mg/min
MMD	3.8 µm
% RF	65%
Average Treatment Time	6-7 min

### Accessories

Bubbles the Fish™ II pediatric mask	044F7248
PARI Adult Aerosol Mask	044F7251

PARI reusable nebulizers were used in the following clinical trials to prove safety and efficacy:

**Pulmicort Respules®** - AstraZeneca

**Perforomist™**, **Accuneb®**, and **Duoneb®** - Dey

**Pulmozyme®** - Genentech, Inc.

**TOBI®** - Novartis

**Xopenex®** and **Brovana®** - Sunovion

<sup>1</sup>Tested with a 1.2 bar compressor. Measured with Malvern MasterSizer X at 50% relative humidity, 0.9% NaCl solution, inspiratory flow 20 liters/minute, continuous nebulization, 23° C, fill volume 2.5 ml.

<sup>2</sup>Insurance coverage varies by provider

<sup>3</sup>Lester, et al. Nebulizer Use and Maintenance by Cystic Fibrosis Patients: A Survey Study. *Respiratory Care* 2004; 49(12): 1504-1508.

<sup>4</sup>Weigand, et al. Using RDDR to Compare Delivery Efficiency of Three Commercially Available Breath-Enhanced Nebulizers with Budesonide. *CHEST* October 2008

<sup>†</sup>Trademarks are the property of their respective companies.